FDA Hits Praxis with 3-Month Delay for Epilepsy Drug Verdict

FDA Delays Praxis' Relutrigine Epilepsy Drug Verdict by 3 Months

Praxis Precision Medicines' investigational epilepsy therapy, relutrigine, faces a three-month delay in its FDA target decision date. The agency classified data from additional analyses as a major amendment, pushing the PDUFA date from September 27 to December 27, 2026. Despite the delay, the FDA did not request additional trials or flag safety/manufacturing concerns. Analysts at Jefferies view this as a "benign delay," emphasizing favorable approval prospects given the lack of critical issues and historical data suggesting high approval rates for such extensions. Relutrigine is being developed for developmental epileptic encephalopathies (DEE) linked to SCN8A and SCN2A mutations.

• The FDA has delayed its target action date for relutrigine by three months, moving it to December 27, 2026, after classifying additional data analyses as a major amendment to the original application. Crucially, the agency did not raise any safety or manufacturing concerns, nor did it request new clinical studies. Jefferies analysts consider this a "fairly benign delay," noting that historical data indicates over 80% of similar review extensions ultimately lead to regulatory approval, reinforcing confidence in relutrigine's approval prospects.
• Relutrigine is an oral sodium channel blocker designed to inhibit the persistent flow of current across sodium channels, which is a key driver of seizures in patients with developmental epileptic encephalopathies (DEE). A mid-stage study for relutrigine in this indication was terminated ahead of schedule in December 2025 due to the drug's strong performance, based on recommendations from an independent data committee, highlighting its significant efficacy.
• Previous mid-stage study results for relutrigine demonstrated a 53% placebo-adjusted reduction in seizures over 16 weeks, and treated patients experienced 66% more motor seizure-free days. These "impressive" results are particularly significant given the limited effective treatment options for the DEE patient population. Praxis anticipates relutrigine could achieve over $1 billion in peak sales specifically for SCN2A/8A-linked DEE.
• Beyond relutrigine, Praxis is advancing other neuroscience assets, including elsunersen, an antisense oligonucleotide for SCN2A DEE, which recently received FDA Breakthrough Therapy Designation and is currently enrolling patients in the pivotal single-arm EMBRAVE3 trial. Additionally, the company announced a successful pre-NDA meeting for ulixacaltamide, an essential tremor drug candidate, with an approval application slated for early 2026, showcasing a robust and diverse pipeline.

Addressing the Unmet Needs in SCN8A/SCN2A DEE

Treatment of SCN8A- and SCN2A-associated DEEs remains substantially limited by the biological complexity of these channelopathies, the heterogeneity of their clinical presentations, and a pervasive pattern of pharmacoresistance. Current standard-of-care approaches fail to adequately address the underlying molecular pathology, leaving patients — many with seizure onset in the first months of life — with poor seizure control, significant neurodevelopmental disability, and elevated SUDEP risk.

• Mechanistic heterogeneity undermines uniform treatment strategies. SCN8A and SCN2A mutations exert diverse functional effects, with some variants producing gain-of-function (GoF) channel activity and others resulting in loss-of-function (LoF) or mixed GoF/LoF profiles. For example, the SCN8A G1625R variant demonstrates a complex mixture of both properties, necessitating personalized, multi-tiered biophysical analysis prior to treatment selection. This variability means that a single therapeutic approach cannot be reliably applied across all mutation carriers.

• Pharmacoresistance is a defining clinical feature. Several DEEs caused by SCN2A and SCN8A mutations present with severe pharmaco-resistant epilepsy. SCN2A L1342P neuronal cultures exhibit resistance to phenytoin, recapitulating clinical observations in patients carrying this variant. While sodium channel blockers are effective or non-aggravating in most SCN8A cases, treatment response remains inconsistent across the mutation landscape.

• Diagnostic complexity delays intervention. SCN8A epilepsy presents across a wide age-of-onset window — from 1 day to 16 months — and includes a slowly emerging onset subtype characterized by rare or subtle seizures and normal interictal EEG. Early clinical events are frequently misidentified as sleep-related movements or non-epileptic movement disorders, delaying accurate diagnosis and timely initiation of appropriate therapy.

• Clinical heterogeneity complicates outcome prediction. SCN8A-related epileptic encephalopathy demonstrates remarkable variability in clinical presentation and treatment response, compounded by the influence of genetic background. The clinical consequences of partial versus complete LoF SCN8A variants, for instance, are variable and likely modulated by modifier loci — as illustrated by the differential impact of Gabra2 alleles on seizure onset and survival in murine models.

• Emerging precision approaches remain largely preclinical. Antisense oligonucleotide (ASO)-mediated reduction of Scn2a expression has demonstrated seizure reduction and significant lifespan extension in GoF mouse models, and viral shRNA delivery targeting Scn8a expression in the dentate gyrus doubled median survival time in SCN8A-N1768D mice. A broader landscape of RNA-based modalities — including antagoNATs, SINEUPs, RNAi, ExSpeU1s, and saRNA — is under investigation. However, translation of these approaches to clinical application in human SCN8A/SCN2A DEE populations is still in early stages.

Relutrigine's Impressive Efficacy and Regulatory Path

Recent preclinical research on SCN8A-related DEE has yielded compelling efficacy data from a 2026 base editing study targeting the pathogenic R1872W gain-of-function variant. In this study, an adenine base editor and guide RNA (SCN8A-ABE) were packaged within dual PhP.eB adeno-associated viruses (AAVs) and administered to R1872W mice at postnatal day 2. The R1872W variant impairs channel inactivation, driving neuronal hyperexcitability and seizures — a mechanism for which current antiseizure medications have proven largely ineffective. SCN8A-ABE significantly increased survival in treated animals, either reducing or fully eliminating seizure occurrence, and achieved suppression of the pathogenic persistent sodium current (INaP) alongside rescue of neuronal hyperexcitability on electrophysiological recordings. These effects were mediated by a 32% absolute reduction in mutant transcripts with concurrent conversion to wild-type SCN8A. Notably, disease-associated comorbidities — including diminished mobility and anxiety-like behaviors — were also improved. No adverse events were explicitly reported in the study description.

For SCN2A-related DEE, recent evidence derives primarily from diagnostic and observational cohort studies rather than interventional trials. A 2026 large diagnostic study — Diagnostic Genetic Findings From Exome Sequencing in a Cohort of 1,109 Children With Epilepsy — identified SCN2A as the third most frequently affected gene (10/1,109; 0.9%) after SCN1A and PRRT2, within an overall diagnostic yield of 36.5%. A 2026 Polish molecular profiling study (Molecular Profiling of Polish Pediatric Patients with Epilepsy), conducted in 87 pediatric patients using next-generation sequencing multi-gene epilepsy panels or whole-exome sequencing, reported the highest proportion of positive diagnoses (48%) in DEE patients, with SCN2A identified among the implicated genes alongside SCN8A, STXBP1, KCNQ2, and others. A concurrent cross-sectional observational study (The Spectrum of Movement Disorders in Children with Genetic Developmental and Epileptic Encephalopathies), enrolling 32 children over January 2024 to January 2025, further documented paroxysmal movement disorders in patients harboring SCN2A variants, with ion channel genes collectively representing the most affected neurobiological pathway at 19% of cases.

Across both mutation subtypes, a 2026 longitudinal audit (Does genetic diagnosis influence long-term seizure and developmental outcomes in childhood developmental and epileptic encephalopathies?) — covering 255 children with DEE and a median follow-up of five years — provides important contextual benchmarks. Seizure freedom was achieved in 40.4% of patients overall, but genetic test positivity did not independently predict seizure freedom or developmental outcome. Positive genetic results were, however, significantly associated with younger age at seizure onset (p < 0.001) and lower likelihood of independent ambulation (p = 0.008). Independent predictors of drug-resistant epilepsy included initial developmental delay (OR 1.87; p = 0.021) and negative family history of seizures (OR 0.55; p = 0.029), while adverse developmental outcomes were predicted by psychomotor delay prior to seizure onset (OR 2.91; p < 0.001), early epilepsy onset (OR 2.15; p = 0.015), and milestone regression (OR 4.13; p < 0.001). These findings underscore both the clinical severity of SCN8A- and SCN2A-linked DEE and the unmet need for precision therapeutics targeting their underlying genetic mechanisms.

Shaping the Future Treatment Landscape for DEE

Over the past five years, the treatment landscape for SCN8A-related DEE has shifted notably toward precision and gene-targeted approaches, moving beyond conventional pharmacotherapy. Sodium channel-blocking agents remain a foundational pharmacological strategy, predicted to be effective based on gain-of-function characteristics of the Nav1.6 channel and corroborated by clinical experience, though treatment options remain limited and adverse effects are common. More transformative has been the emergence of gene-targeted interventions: targeted reduction of Scn8a expression via viral delivery of shRNA to the dentate gyrus doubled median survival time from four to eight months in mice expressing the patient mutation SCN8A-p.Asn1768Asp (N1768D), while delivery to CA1 and CA3 regions conferred no survival benefit, underscoring the circuit-specific relevance of this approach. Most recently, adenine base editing using a dual PhP.eB-AAV-packaged SCN8A-ABE system administered to R1872W mice achieved a 32% absolute reduction in mutant transcripts with concurrent conversion to wild-type, rescued seizure-associated neuronal hyperexcitability, suppressed pathogenic persistent sodium current (INaP), and improved behavioral comorbidities including diminished mobility and anxiety-like phenotypes.

For SCN2A-related DEE, the field has similarly advanced from clinical observation toward mechanistically informed therapeutic development. A critical insight shaping treatment strategy is the recognition that pharmacosensitivity diverges according to variant dysfunction class: gain-of-function (GoF) variants presenting with pre- or perinatal seizures respond to sodium channel blockers such as phenytoin, which has been shown to reduce neuronal excitability to control levels in R1882Q neuronal cultures, consistent with reported clinical efficacy in GoF patients. Conversely, loss-of-function (LoF) variants, typically manifesting as infantile spasms after six months of age, represent a distinct pharmacological subpopulation. At the preclinical level, central administration of a gapmer antisense oligonucleotide (ASO) targeting Scn2a mRNA in Q/+ mice — a model of early-onset SCN2A DEE — reduced spontaneous seizures, significantly extended lifespan beyond the untreated ceiling of postnatal day 30, and produced behavioral profiles largely indistinguishable from wild-type animals, suggesting favorable tolerability and supporting translation of a human SCN2A gapmer ASO.

Underpinning these therapeutic advances is the expanding role of next-generation sequencing (NGS) and whole exome sequencing (WES) as first-tier diagnostic tools, which have broadened the scope of precision medicine in epileptic encephalopathy by enabling earlier etiological diagnosis, guiding genotype-informed treatment selection, and facilitating genetic counseling. The importance of SCN2A mutational screening has been further highlighted in cases of intellectual disability and autism spectrum disorder with or without epilepsy. Collectively, the published data from the past five years reflect a maturing pipeline in which mechanistic stratification by variant function class, region-specific gene silencing, and RNA-targeted therapeutics are progressively redefining what is clinically achievable in SCN8A- and SCN2A-related DEE.